[Skip to Content]
[Skip to Content Landing]

Lip Squamous Cell Carcinoma With Spontaneous Eruption and Drainage

Educational Objective
Based on this clinical scenario and the accompanying image, understand how to arrive at a correct diagnosis.
1 Credit CME

A 69-year-old woman with a newly diagnosed T3N2cM0 poorly differentiated squamous cell carcinoma unrelated to human papillomavirus (HPV) of the lower lip mucosa presented to the medical oncology clinic 3 days after initiating neoadjuvant immune checkpoint blockade immunotherapy with redness and swelling of the tumor site. Four days after treatment, a white head formed overlying the tumor that erupted through the skin surface (Figure 1). Thin, cloudy discharge that was not foul-smelling drained from the tumor from posttreatment days 5 to 10, at which point the drainage stopped spontaneously. Throughout, the patient reported no pain and remained afebrile. Laboratory results on days 5, 9, and 14 demonstrated the absence of leukocytosis, and serial wound cultures failed to demonstrate pathogenic growth. No antibiotics were administered. The patient completed the neoadjuvant immunotherapy and underwent a margin-negative tumor resection without intraoperative or postoperative complications.

Please finish quiz first before checking answer.

You answered correctly!

Read the answer below and download your certificate.

You answered incorrectly.

Read the discussion below and retake the quiz.

B. Immunotherapy-related inflammation

Tumor liquification possibly resulting from rapid necrosis of the tumor during immunotherapy can represent a positive response to treatment and immunotherapy-associated tumor death. Although unknown at the time, retrospective study of this patient’s surgical specimen revealed evidence of pathologic response with a substantial degree of tumor necrosis and viable primary tumor regression of 20% within the fibrotic tumor bed (Figure 2).1,2 Histologic analysis of the resected primary tumor specimen also revealed evidence of heavy immune infiltrate distributed throughout the tumor. Interestingly, this patient was clinically classified with N2c disease at the time of diagnosis based on positron emission and contrast-enhanced computed tomography imaging but was found to be pathologically N0 upon analysis of her surgical specimen.1 Such data indicate that immune checkpoint blockade–based neoadjuvant immunotherapy may result in significant pathologic responses prior to surgery in both the primary tumor and regional lymph node metastases.

Survey Complete!

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Wojciech K. Mydlarz, MD, Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins University School of Medicine, JHOC 6210, 601 N Caroline St, Baltimore, MD 21287 (mydlarz@jhmi.edu).

Published Online: February 2, 2023. doi:10.1001/jamaoto.2022.4828

Conflict of Interest Disclosures: Dr Toni reported involvement with a Medical Research Scholars Program fellowship from the National Institutes of Health (NIH) during the submitted work. No other disclosures were reported.

Additional Contributions: We thank Chyi-Chia Richard Lee, MD, PhD, for his evaluation of the pathology specimen and critical review of the manuscript. This individual was not compensated for their contributions. We also thank the patient for granting permission to publish this information.

Additional Information: This research was made possible through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation, the American Association for Dental Research, the Colgate-Palmolive Company, and other private donors. For a complete list, please visit the Foundation website at http://fnih.org/what-we-do/current-education-and-training-programs/mrsp.

References
1.
Redman  JM , Friedman  J , Robbins  Y ,  et al.  Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.   J Clin Invest. 2022;132(18):e161400. doi:10.1172/JCI161400Google ScholarCrossref
2.
Stein  JE , Lipson  EJ , Cottrell  TR ,  et al.  Pan-tumor pathologic scoring of response to PD-(L)1 blockade.   Clin Cancer Res. 2020;26(3):545-551. doi:10.1158/1078-0432.CCR-19-2379PubMedGoogle ScholarCrossref
3.
Shibata  H , Saito  S , Uppaluri  R .  Immunotherapy for head and neck cancer: a paradigm shift from induction chemotherapy to neoadjuvant immunotherapy.   Front Oncol. 2021;11:727433. doi:10.3389/fonc.2021.727433PubMedGoogle ScholarCrossref
4.
Merck Sharp & Dohme LLC. Study of pembrolizumab given prior to surgery and in combination with radiotherapy given post-surgery for advanced head and neck squamous cell carcinoma (MK-3475-689). Updated December 2022. https://clinicaltrials.gov/ct2/show/NCT03765918
5.
Chiou  VL , Burotto  M .  Pseudoprogression and immune-related response in solid tumors.   J Clin Oncol. 2015;33(31):3541-3543. doi:10.1200/JCO.2015.61.6870PubMedGoogle ScholarCrossref
AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close